The report covers forecast and analysis for the depression drug market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Million). The study includes drivers and restraints for the depression drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes study of opportunities available in the depression drug market on a global level.
In order to give the users of this report a comprehensive view on the depression drug market, we have included a detailed competitive scenario, and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter&rsquos five forces model for the depression drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.
The study provides a decisive view on the depression drug market by segmenting the market based class and region. The different classs of depression also have different symptoms, including major or clinical depressive disorder, postpartum depression, dysthymic disorder, psychotic depression and seasonal affective disorder. Depending upon class global depression drug market is segmented as anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs) and monoamine oxidase inhibitors (MAOIs) among others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil.
The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Forest Laboratories, AstraZeneca, GlaxoSmithKline, Abbott Laboratories, H. Lundbeck, Novartis, SK Biopharmaceuticals, Naurex Merck & Co., and Eli Lilly and Company.
This report segments the global drug depression market as follows:
Global Depression Drug Market: Class Segment Analysis
Atypical Antipsychotics
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Tetracyclic Antidepressants
Monoamine Oxidase inhibitors
Benzodiazepines
Others
Global Depression Drug Market: Regional Segment Analysis
North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
Table of Content
Chapter 1. Introduction
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
Chapter 2. Executive Summary
2.1. Global market revenue, 2014 - 2020(USD Million)
2.2. Global depression drug market: Snapshot
Chapter 3. Depression drug market – Global and Industry Analysis
3.1. Depression drug: Market dynamics
3.2. Market drivers
3.2.1. Drivers of global depression drug market: Impact analysis
3.2.2. Escalating prevalence of anxiety and depression disorders
3.2.3. Rising efficiency and declining side effects of drugs in numerous classes
3.3. Market restraints
3.3.1. Restraints of global depression drug market: Impact analysis
3.3.2. Expiry of main antidepressants
3.3.3. Weak pipeline of new drugs
3.4. Opportunities
3.4.1. Small market penetration in developing countries
3.5. Porter’s five forces analysis
3.6. Market Attractiveness Analysis
3.6.1. Market attractiveness analysis by class segment
3.6.2. Market attractiveness analysis by regional segment
Chapter 4. Global Depression drug market - Competitive Landscape
4.1. Company market share, 2014
4.2. Price trend analysis
Chapter 5. Global Depression drug market : Class Overview
5.1. Global depression drug market share, by class, 2014 and 2020
5.2. Global depression drug market for atypical antipsychotics, 2014 - 2020 (USD Million)
5.3. Global depression drug market for tricyclic antidepressants, 2014 - 2020 (USD Million)
5.4. Global depression drug market for selective serotonin reuptake inhibitors, 2014 - 2020 (USD Million)
5.5. Global depression drug market for tetracyclic antidepressants, 2014 – 2020 (USD Million)
5.6. Global depression drug market for monoamine oxidase inhibitors, 2014 – 2020 (USD Million)
5.7. Global depression drug market for benzodiazepines, 2014 – 2020 (USD Million)
5.8. Global depression drug market for others, 2014 – 2020 (USD Million)
Chapter 6. Global Depression drug market – Regional Segment Analysis
6.1. Global depression drug market : Regional overview
6.1.1. Global depression drug market revenue share, by region, 2014 and 2020
6.2. North America
6.2.1. North America depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.3. Europe
6.3.1. Europe depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.3.2. Germany
6.3.2.1. Germany depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.3.3. France
6.3.3.1. France depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.3.4. UK
6.3.4.1. U.K. depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.4.2. China
6.4.2.1. China depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.4.3. Japan
6.4.3.1. Japan depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.4.4. India
6.4.4.1. India depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.5. Latin America
6.5.1. Latin America depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil depression drug market revenue, by class, 2014 – 2020 (USD Million)
6.6. Middle East Africa
6.6.1. Middle East Africa depression drug market revenue, by class, 2014 – 2020 (USD Million)
Chapter 7. Company Profile
7.1. Forest Laboratories
7.1.1. Overview
7.1.2. Financials
7.1.3. Product portfolio
7.1.4. Business strategy
7.1.5. Recent developments
7.2. AstraZeneca
7.2.1. Overview
7.2.2. Financials
7.2.3. Product portfolio
7.2.4. Business strategy
7.2.5. Recent developments
7.3. Eli Lilly and Company
7.3.1. Overview
7.3.2. Financials
7.3.3. Product portfolio
7.3.4. Business strategy
7.3.5. Recent developments
7.4. H. Lundbeck, Merck Co.
7.4.1. Overview
7.4.2. Financials
7.4.3. Product portfolio
7.4.4. Business strategy
7.4.5. Recent developments
7.5. GlaxoSmithKline
7.5.1. Overview
7.5.2. Financials
7.5.3. Product portfolio
7.5.4. Business strategy
7.5.5. Recent developments
7.6. Naurex
7.6.1. Overview
7.6.2. Financials
7.6.3. Product portfolio
7.6.4. Business strategy
7.6.5. Recent developments
7.7. Novartis
7.7.1. Overview
7.7.2. Financials
7.7.3. Product portfolio
7.7.4. Business strategy
7.7.5. Recent developments
7.8. SK Biopharmaceuticals
7.8.1. Overview
7.8.2. Financials
7.8.3. Product portfolio
7.8.4. Business strategy
7.8.5. Recent developments
